By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) and its U.S. partner Kailera Therapeutics announced positive topline results from the Phase III OUTSTAND-1 trial evaluating HRS-7535 (KAI-7535 outside Greater China), a once-daily oral small-molecule GLP-1 receptor agonist, in 284 Chinese adults with type 2 diabetes.
Clinical Trial Results – OUTSTAND-1 Phase III
| Endpoint | 30 mg Dose | 60 mg Dose | 90 mg Dose |
|---|---|---|---|
| Primary Endpoint HbA1c Reduction (32 weeks) | -1.40% | -1.55% | -1.68% |
| Key Secondary Endpoint Patients Achieving HbA1c <7.0% | 83.5% | 86.2% | 89.6% |
| Study Population | 284 Chinese adults with type 2 diabetes | ||
| Treatment Duration | 32 weeks |
Product Profile & Differentiation
- Molecule: Self-developed oral GLP-1 receptor agonist
- Dosing Convenience: Once-daily administration with no food or fasting restrictions
- Patient Flexibility: Can be taken with food and water without impacting efficacy or absorption
- Development Status: Lead candidate in Hengrui’s comprehensive GLP-1 franchise
- Global Branding: HRS-7535 (Greater China) / KAI-7535 (ex-Greater China)
Broader Development Portfolio
Diabetes Program – OUTSTAND Series
- OUTSTAND-1: Completed Phase III in type 2 diabetes (reported)
- Additional studies ongoing to support regulatory submissions
Weight Management Program – HARBOR Series
- Multiple Phase II/III trials active in China
- Targeting obesity and weight-related comorbidities
Chronic Kidney Disease Program – RENEW-CKD Trial
- Phase II/III study evaluating renal protective effects
- Addresses significant unmet need in diabetic kidney disease
Strategic Partnership Framework
| Aspect | Hengrui Pharmaceuticals | Kailera Therapeutics |
|---|---|---|
| Territory | Greater China (China, Hong Kong, Macau, Taiwan) | Ex-Greater China (global) |
| Rights Granted | Retained exclusive rights | Exclusive development, manufacturing, and commercialization rights |
| Agreement Date | May 2024 | May 2024 |
| Current Development | OUTSTAND, HARBOR, and RENEW-CKD trials in China | Global Phase II obesity trial (data expected 2027) |
Market Context & Competitive Landscape
- GLP-1 Market Size: $25+ billion global market projected to exceed $50 billion by 2030
- Oral Delivery Advantage: Addresses patient preference for pill-based vs. injectable therapies
- Competitive Positioning: Competes with Novo Nordisk’s Rybelsus while offering potential dosing flexibility advantages
- Commercial Timeline: Regulatory submissions expected in 2027 following completion of additional Phase III studies
- Revenue Potential: Peak sales estimates range from $1-3 billion annually depending on global market penetration
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory timelines, and commercial expectations for HRS-7535/KAI-7535. Actual results may differ due to risks including regulatory decisions, competitive dynamics, clinical trial outcomes, and market access challenges.-Fineline Info & Tech